Boston Scientific announced a $2 billion accelerated share repurchase (ASR) agreement with JPMorgan Chase, acquiring about 30.4 million shares based on May 15 closing prices. This ASR is part of a larger $5 billion share repurchase authorization, leaving $3 billion available after this transaction. The final number of shares repurchased will depend on the average stock price during the ASR period, with completion expected by June 30, 2026. The buyback is expected to increase adjusted earnings per share by $0.02 in 2026, supporting the company’s earnings guidance.
Boston Scientific has invested $1.5 billion to acquire about a 34% stake in MiRus, gaining exclusive rights to its investigational transcatheter aortic valve replacement (TAVR) system designed for severe aortic stenosis. The SIEGEL valve features a n...
Boston Scientific has invested $1.5 billion to acquire approximately 34% equity in MiRus LLC, a company developing innovative cardiovascular implants including the SIEGEL Balloon Expandable Transcatheter Aortic Valve Replacement (TAVR) system. This i...
Boston Scientific's stock has dropped over 43% year-to-date, wiping out years of gains due to lowered guidance and weakness in key segments like WATCHMAN and Urology. Despite this, a new Buy rating has been initiated, citing achievable guidance after...
